1. Garcia-Ruiz A, Costillas LP, Montesinos AC, Alcalde J, Oyagüez I, Casado M: Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012. doi: 10.1186/2191-1991-2-8 .
2. Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P: Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr. 2010. doi: 10.1186/1478-7954-8-24 .
3. Piccinelli M, Gomez Homen F: Gender differences in the epidemiology of affective disorders and schizophrenia, Division of Mental Health and Prevention of substance abuse. Ed World Health Organization. 1997. http://whqlibdoc.who.int/hq/1997/WHO_MSA_NAM_97.1.pdf . Accessed 8 Oct 2012.
4. Knapp M, Mangalore R, Simon J: The Global Costs of Schizophrenia. Schizophr Bull. 30:279–293, 2004.
5. Nowakowska E: Pharmacoeconomic research methodology. In: Nowakowska E, editor. Pharmacoeconomics-cooperation work. Poznań: Dział Wydawnictw Uczelnianych UMiKM; 2009. pp. 20–40.